Overview

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Status:
Not yet recruiting
Trial end date:
2025-01-15
Target enrollment:
Participant gender:
Summary
A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
Phase:
Phase 2
Details
Lead Sponsor:
EyePoint Pharmaceuticals, Inc.
Treatments:
Aflibercept